Patents by Inventor Justin Guild

Justin Guild has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS
    Publication number: 20240131193
    Abstract: The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.
    Type: Application
    Filed: January 30, 2023
    Publication date: April 25, 2024
    Inventors: Antonin DE FOUGEROLLES, Justin GUILD
  • Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
    Patent number: 11564998
    Abstract: The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: January 31, 2023
    Assignee: ModernaTX, Inc.
    Inventors: Antonin De Fougerolles, Justin Guild
  • MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS
    Publication number: 20220273555
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Application
    Filed: April 28, 2020
    Publication date: September 1, 2022
    Inventors: Stephane BANCEL, Tirtha CHAKRABORTY, Antonin DE FOUGEROLLES, Sayda M. ELBASHIR, Matthias JOHN, Atanu ROY, Susan WHORISKEY, Kristy M. WOOD, Paul HATALA, Jason P. SCHRUM, Kenechi EJEBE, Jeff Lynn ELLSWORTH, Justin GUILD
  • MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE
    Publication number: 20210299278
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Application
    Filed: September 14, 2020
    Publication date: September 30, 2021
    Inventors: Stephane BANCEL, Tirtha CHAKRABORTY, Antonin DE FOUGEROLLES, Sayda M. ELBASHIR, Matthias JOHN, Atanu ROY, Susan WHORISKEY, Kristy M. WOOD, Paul HATALA, Jason P. SCHRUM, Kenechi EJEBE, Jeff Lynn ELLSWORTH, Justin GUILD
  • MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
    Publication number: 20210115101
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Application
    Filed: October 28, 2019
    Publication date: April 22, 2021
    Inventors: Stephane BANCEL, Tirtha CHAKRABORTY, Antonin DE FOUGEROLLES, Sayda M. ELBASHIR, Matthias JOHN, Atanu ROY, Susan WHORISKEY, Kristy M. WOOD, Paul HATALA, Jason P. SCHRUM, Kenechi EJEBE, Jeff Lynn ELLSWORTH, Justin GUILD
  • IN VIVO PRODUCTION OF PROTEINS
    Publication number: 20210077634
    Abstract: The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.
    Type: Application
    Filed: March 6, 2020
    Publication date: March 18, 2021
    Inventors: Antonin DE FOUGEROLLES, Justin GUILD
  • MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS
    Publication number: 20200354423
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Application
    Filed: July 2, 2020
    Publication date: November 12, 2020
    Inventors: Antonin DE FOUGEROLLES, Justin GUILD
  • Modified Polynucleotides for the production of biologics and proteins associated with human disease
    Patent number: 10772975
    Abstract: The invention relates to a pharmaceutical composition including a plurality of lipid nanoparticles having a mean particle size of between 80 nm and 160 nm and containing an mRNA encoding a polypeptide. The lipid nanoparticles include a cationic lipid, a neutral lipid, a cholesterol, and a PEG lipid. The mRNA contains a 5?-cap, 5?-UTR, a 3?-UTR, and a poly-A region with at least 100 nucleotides.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: September 15, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin De Fougerolles, Sayda M. Elbashir, Matthias John, Atanu Roy, Susan Whoriskey, Kristy M. Wood, Paul Hatala, Jason P. Schrum, Kenechi Ejebe, Jeff Lynn Ellsworth, Justin Guild
  • MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES
    Publication number: 20200247861
    Abstract: The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.
    Type: Application
    Filed: December 9, 2019
    Publication date: August 6, 2020
    Inventors: Antonin DE FOUGEROLLES, Justin GUILD
  • Modified polynucleotides for the production of secreted proteins
    Patent number: 10703789
    Abstract: A pharmaceutical composition which has a plurality of lipid nanoparticles that has a mean particle size of between 80 nm and 160 nm and contains a modified mRNA encoding a polypeptide. The lipid nanoparticles include a cationic lipid, a neutral lipid, a cholesterol, and a PEG lipid. The mRNA contains a 5?-cap, 5?-UTR, N1-methyl-pseudouridine, a 3?-UTR, and a poly-A region with at least 100 nucleotides.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: July 7, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Antonin De Fougerolles, Justin Guild
  • MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS
    Publication number: 20200155706
    Abstract: The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.
    Type: Application
    Filed: September 20, 2019
    Publication date: May 21, 2020
    Inventors: Antonin DE FOUGEROLLES, Justin GUILD
  • In vivo production of proteins
    Patent number: 10583203
    Abstract: The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: March 10, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Antonin De Fougerolles, Justin Guild
  • Modified polynucleotides for the production of secreted proteins
    Patent number: 10577403
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: March 3, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Antonin De Fougerolles, Justin Guild
  • MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS
    Publication number: 20200017565
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Application
    Filed: June 12, 2019
    Publication date: January 16, 2020
    Applicants: ModernaTX, Inc., ModernaTX, Inc.
    Inventors: Antonin DE FOUGEROLLES, Justin GUILD
  • Modified polynucleotides
    Patent number: 10501512
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Grant
    Filed: March 9, 2013
    Date of Patent: December 10, 2019
    Assignee: ModernaTX, Inc.
    Inventors: Antonin De Fougerolles, Justin Guild
  • Modified polynucleotides for the production of oncology-related proteins and peptides
    Patent number: 10501513
    Abstract: The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: December 10, 2019
    Assignee: ModernaTX, Inc.
    Inventors: Antonin De Fougerolles, Justin Guild
  • In vivo production of proteins
    Patent number: 10493167
    Abstract: The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: December 3, 2019
    Assignee: ModernaTX, Inc.
    Inventors: Antonin de Fougerolles, Justin Guild
  • Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
    Patent number: 10463751
    Abstract: The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: November 5, 2019
    Assignee: ModernaTX, Inc.
    Inventors: Antonin De Fougerolles, Justin Guild
  • IN VIVO PRODUCTION OF PROTEINS
    Publication number: 20190314527
    Abstract: The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.
    Type: Application
    Filed: June 14, 2019
    Publication date: October 17, 2019
    Inventors: Antonin DE FOUGEROLLES, Jason P. SCHRUM, Justin GUILD
  • MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS
    Publication number: 20190315824
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Application
    Filed: June 12, 2019
    Publication date: October 17, 2019
    Applicants: ModernaTX, Inc., ModernaTX, Inc.
    Inventors: Antonin DE FOUGEROLLES, Justin GUILD